Danny L. Dearen
Known title: DirectorCIK: 0001756438
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
InspireMD (NSPR) noted in pre‑market health‑care stock moves. NSPR was listed among twelve health‑care companies showing price action in Friday’s pre‑market session, according to Benzinga. The move comes while the stock’s RSI is low at 25.7 and it is near its $0.70 support level, suggesting continued pressure. Such activity may reflect renewed trader attention despite the broader market context.
Transaction History
| BBNX | ▲ Buy | Grant | 16,965 | $0 | 5/21/2026 | View on chart |
| NSPR | ▲ Buy | Grant | 44,030 | $0 | 1/14/2026 | View on chart |
| BBNX | ▲ Buy | Grant | 3,997 | $0 | 1/13/2026 | View on chart |
| BBNX | ▲ Buy | Grant | 11,247 | $0 | 3/15/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Beta Bionics Signs Senseonics Deal, Gets New Analyst Coverage
Beta Bionics announced an agreement to integrate its iLet Bionic Pancreas with Senseonics' Eversense 365 sensor. This partnership aims to create a more comprehensive automated insulin delivery system. Additionally, Wells Fargo initiated coverage with an Overweight rating and a $28 price target, while Truist raised its target to the same level. The stock is currently trading within its 52-week range, with an average analyst target of $22.40.
Beta Bionics Signs Senseonics Deal, Gets New Analyst Coverage. Beta Bionics announced an agreement to integrate its iLet Bionic Pancreas with Senseonics' Eversense 365 sensor. This partnership aims to create a more comprehensive automated insulin delivery system. Additionally, Wells Fargo initiated coverage with an Overweight rating and a $28 price target, while Truist raised its target to the same level. The stock is currently trading within its 52-week range, with an average analyst target of $22.40.